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of Immunohis tochemical Markers Estrogen Receptor ,
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By Sunil R. Lakhani, Marc J. van de Vijver, Jocelyne Jacquemier, Thomas J. Anderson, Peter P. Osin, Lesley McGuffog,
and Douglas F. Easton for the Breast Cancer Linkage Consortium
Purpose: The morphologic and molecular pheno-
type of breast cancers may help identify patients who
are likely to carry germline mutations in BRCA1 and
BRCA2. This study evaluates the immunohistochemical
profiles of tumors arising in patients with mutations in
these genes.
Materials and Methods: Samples of breast cancers
obtained from the International Breast Cancer Linkage
Consortium were characterized morphologically and
immunohistochemically using antibodies to estrogen
receptor, progesterone receptor, HER-2 (c-erbB-2 onco-
gene), and p53 protein.
Results: Breast cancers in patients with BRCA1 germ-
line mutations are more often negative for estrogen re-
ceptor, progesterone receptor, and HER-2, and are more
likely to be positive for p53 protein compared with con-
trols. In contrast, BRCA2 tumors do not show a significant
difference in the expression of any of these proteins
compared with controls.
Conclusion: BRCA1 has a distinctive morphology
and immunohistochemical phenotype. The combined
morphologic and immunohistochemical data can be
used to predict the risk of a young patient harboring a
germline mutation in BRCA1. The BRCA2 phenotype is
currently not well defined.
J Clin Oncol 20:2310-2318. © 2002 by American
Society of Clinical Oncology.
IN A LARGE COLLABORATIVE study carried out onbehalf of the Breast Cancer Linkage Consortium, we
have characterized the histopathologic features of breast
cancers arising in patients harboring germline mutations in
the BRCA1 and BRCA2 genes.1,2 Breast cancers in patients
with BRCA1 mutations were of higher grade and had higher
mitotic counts, a greater degree of nuclear pleomorphism,
and less tubule formation than age-matched sporadic breast
cancers unselected for family history. BRCA1 carriers also
had an excess of medullary and atypical medullary cancers.
However, multifactorial analysis demonstrated that many of
these factors were associated with each other. A high
mitotic count, presence of a lymphocytic infiltrate, and the
presence of a smooth noninfiltrative pushing border were
independently associated with BRCA1, but all other features
became nonsignificant.
Breast cancers caused by BRCA2 mutations were also of
higher overall grade as a result of exhibiting less tubule
formation, but were not significantly different from controls
with respect to mitoses and pleomorphism. In the multifac-
torial analysis, both the reduction in tubule formation and
the presence of continuous pushing margins were signifi-
cantly associated with BRCA2. The findings with respect to
BRCA1 are broadly in agreement with other series, but only
a limited number of breast cancers caused by BRCA2 have
been evaluated in detail by other groups.3-11
The use of immunohistochemical and molecular analysis
of cancer-associated genes and the encoded proteins has
been important in understanding tumor biology. Immuno-
histochemical studies in sporadic cancers have led to iden-
tification of novel targets with roles in diagnosis, prognos-
tication, and therapeutics. Examples include hormones (eg,
estrogen receptor) and growth factor receptors (eg, epider-
mal growth factor receptor), tumor-specific oncogene prod-
ucts (eg, HER-2), and cell cycle proteins (eg, cyclin D1).
The development of Herceptin (Genentech, Inc, San Fran-
cisco, CA), a humanized monoclonal antibody against
HER-2, is a triumph in translation of molecular and cell
biology to the clinic.12
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In this report, we present the immunohistochemical
profile (estrogen receptor [ER], progesterone receptor [PR],
HER-2, and p53) of tumors associated with mutations in
BRCA1 and BRCA2 genes. Clearly, this question is of more
than just scientific curiosity, because the phenotype of the
tumor may provide vital diagnostic and prognostic informa-
tion for the patient. Although genetic testing for BRCA1 and
BRCA2 mutations within high-risk families is available, it is
expensive and is associated with psychological morbidity.13
The morphologic and molecular phenotype of breast can-
cers may help identify patients who are likely to carry
mutations in these genes.
MATERIALS AND METHODS
Breast Cancer Specimens
We reviewed 182 tumors from 119 families in BRCA1 mutation
carriers, 63 tumors from 34 families in BRCA2 carriers, and 109 control
tumors. Twenty-one familial cases in which no BRCA1 or BRCA2
mutation could be found were also reviewed but are not included in
these analyses. After exclusion of tumors where there was no evidence
of invasion, or where the primary site appeared to be other than the
breast, the final analyses were derived from tumors from 165 individ-
uals from BRCA1 families, 52 individuals from BRCA2 families, and
103 controls. Two cases from mutation-positive families who were
known not to carry the mutation were excluded. Samples were analyzed
for morphologic features using the same format as in the previous
reviews.2,14 We obtained specimens from case subjects with familial
breast cancer in the form of blocks or unstained 3-m-thick sections
from the United Kingdom, United States, Ireland, France, Germany,
Iceland, Switzerland, Italy, Hungary, and the Netherlands. The control
set of breast cancers was drawn from the archives of University College
Hospital, London. Cases were selected at random such that the
frequency of controls in each decade of age was similar to that in the
familial cases.14 The cases were identified only by an allocated number
and not by personal details. A computer-generated random number was
allocated to each case familial and control sample.
Immunohistochemistry
Sections 3 m thick were cut onto DAKO Capillary Gap slides
(S2024) (DAKO Corp, Carpinteria, CA) and dried at 60°C overnight.
Slides were dewaxed in xylene, taken to absolute alcohol, and incu-
bated in 3% hydrogen peroxide in methanol for 10 minutes to block
endogenous peroxidase. The slides were then transferred to running tap
water before pressure cooking.
Slides were transferred to 3 L of boiling citrate buffer pH 6.0 in a
15-lb pressure cooker. Once full pressure was achieved, the slides were
cooked for 2 minutes and the pressure cooker flushed with tap water.
After antigen retrieval, slides were rinsed in Tris-buffered saline
(TBS) pH 7.4 and incubated in normal goat serum (1:10) for 10
minutes. The serum was tipped off and the sections incubated in
primary antibody for 60 minutes at the appropriate dilution (Table 1).
The slides were rinsed in TBS and incubated in DAKO Duet (K0492)
biotinylated goat antimouse/rabbit secondary reagent (1:100) for 35
minutes. After rinsing in TBS, the slides were then incubated in DAKO
Duet (K0492) streptavidin-biotin–horseradish peroxidase complex for
35 minutes, rinsed in TBS, and treated with DAB chromogen (896102,
Kem-En-Tec, Copenhagen, Denmark) for 10 minutes. The slides were
then rinsed in tap water, counterstained in Mayer’s hematoxylin, and
mounted in synthetic mountant.
Conduct of the Histologic Review
In the review, each slide was read independently by two pathologists
(two of M.J.V., P.P.O., T.J.A., and J.J.). Because the slides were
arranged in order according to a random number, the pathologists were
not aware of whether the slide being read was from a case subject or a
control subject. No attempt was made to reconcile differences between
pathologists, as it was difficult to design such a process that would not
introduce other biases. For ER, PR, and p53, the intensity of staining
was recorded as negative, low, moderate, or strong. The pathologists
were provided with identical color charts to aid consistency in scoring
the intensity of the staining (ranging from white [negative] to dark
brown [strong]). The proportion of positive cells was divided into six
categories; 0 to less than 1%, 1% to 5%, 6% to 25%, 26% to 50%, 51%
to 75%, and more than 75%. For HER-2, tumors in which the majority
( 75%) of cells showed a strong complete membrane staining
(equivalent to score 3, DAKO scoring system) were classed as positive.
All other cases were recorded as negative.
Classification of Families
Familial cases were attributed to BRCA1 or BRCA2 on the basis of
either a mutation clearly associated with disease or strong linkage
evidence generating a more than 90% posterior probability of being
caused by one or the other gene, as described previously.1,2 We made
the assumption that cases in mutation-positive families were mutation
carriers unless information from mutation or linkage analyses indicated
that they were noncarriers (these noncarriers were excluded from all
analyses). In practice, only one family was attributed to BRCA1 and
one family to BRCA2 on the basis of linkage alone.
Statistical Methods
We performed separate analyses comparing tumors in BRCA1
carriers and BRCA2 carriers with control tumors. As in the previous
analyses, the effects of each morphologic feature on cancer status were
summarized in terms of odds ratios. All analyses were adjusted for age,
in groups less than 30, 30 to 39, 40 to 49, 50 to 59, and 60 to 69 years,
by the pathologist conducting the immunohistochemical and by the
pathologist conducting the morphologic review. These adjusted anal-
yses were carried out using multiple logistic regression analysis, using
the program S-Plus (Version 3.4, MathSoft, Inc, Seattle, WA).
The main complication in the analysis is that the observations by
different pathologists on the same slide cannot be considered indepen-
dent. Using standard logistic regression therefore leads to unbiased
odds ratio estimates but underestimates their standard errors and
confidence intervals. To correct for this, we computed confidence limits
Table 1. Details of Antibodies Used in the Study
Antibody Dilution Supplier
ER 1:30 DAKO M7047
PR 1:40 Novacastra NCL-
p53 (DO-7) 1:50 DAKO M7001
HER-2 1:10o/n Novacastra NCL-
Abbreviation: o/n, incubated in primary antibody overnight at room
temperature.
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using the robust Huber’s sandwich estimator for the variance-covari-
ance matrix of maximum quasi-likelihood estimates (18) using spe-
cially written S-Plus macros. This quasi-likelihood approach allows for
the variation in scoring individual samples between the pathologists
without explicitly modeling the error distribution. Significance levels
for each factor were derived from the parameter estimates and the
covariance matrix (adjusted using the sandwich estimator). Signifi-
cance tests for the effects of intensity of staining and percentage of cells
stained on carrier probability were constructed as 1 degree of freedom
tests on the basis of testing for linear trends in log (odds ratio) with
increasing category.15 Estimated odds ratios were, however, derived
separately for each level. Significance levels less than .10 are quoted in
the tables. Heterogeneity 2 statistics (based on k  1 degree of
freedom for factors with k levels) have also been presented for those
factors with the best fitting models.
To determine which factors were independently predictive of genetic
status, we also performed multiple regression analyses. In these
analyses, all factors that were significant at the 5% level in either the
BRCA1 or BRCA2 analysis, together with age of the patient and
pathologist who reviewed the slides, were initially included. Factors
(other than age and pathologist) were then removed from the model
on a stepwise basis until no further factors could be removed at the
5% level.
Concordance between pathologists was assessed using kappa statis-
tics. For characteristics on an ordinal scale (ie, intensity of staining and
percentage of cells stained), weighted kappa statistics were used.
Confidence limits were constructed by bootstrapping, using 1,000
bootstrap replicates.
To derive the predicted BRCA1 carrier probabilities on the basis of
pathologic status, we used the predicted carrier probabilities for breast
cancer cases at different ages derived from a previous population-based
segregation analysis of breast cancer.16 The predicted carrier probabil-
ities were then derived from the frequency of each pathologic subgroup
in each age group and the estimated odds ratios from the model, so as
to agree with the overall BRCA1 carrier probability.
RESULTS
The kappa coefficients for interobserver variation for the
different characteristics are listed in Table 2. Coefficients
are highest for ER and lowest for PR and p53, but all
coefficients are reasonably high.
Table 3 lists the distributions of immunohistochemical
features in BRCA1 and BRCA2 tumors and controls. The
corresponding odds ratios for each factor, adjusted for age
and pathologist, are listed in Table 4. There was a highly
significant difference in the distribution of ER status be-
tween BRCA1 tumors and controls (P  .0001). Only 10%
of BRCA1 tumors showed any positive staining for ER,
compared with 65% of controls. In contrast, BRCA2 tumors
showed a distribution of ER staining similar to controls (in
terms of both intensity and percentage of cells stained), with
66% of tumors being positive. BRCA1 carriers were also
significantly less likely to be PR-positive, although the
effect was slightly weaker than for ER (21% v 59%, P 
.0001). Again, the distribution of PR status in BRCA2
carriers (55% positive) was similar to that in controls.
BRCA1 tumors were significantly less likely to show
positive staining of HER-2 (3% v 15% in controls; P 
.018). The frequency of HER-2 positivity in BRCA2
tumors (3%) was similar to that in BRCA1 tumors,
although this was not significantly different from the
frequency in controls.
p53 staining showed a more complex relationship with
carrier status. The distribution of p53 staining was signifi-
cantly different between BRCA1 tumors and controls (P 
.006). However, the BRCA1 group contained a lower
frequency of tumors with low-intensity staining than with
no staining (odds ratio, 0.32), but a higher frequency of
tumors with high-intensity staining (oddss ratio, 2.28). A
similar pattern was seen with percentage of cells stained,
with a reduced frequency of tumors with 1% to 10% cells
stained (odds ratio, 0.31), but an increasing trend thereafter,
reaching an odds ratio of 3.19 for tumors with more than
75% cells stained. There was some suggestion of a similar
effect in BRCA2 tumors, although this was not significant.
The factors that were individually significant predictors
of BRCA1 status (ER, PR, and HER-2) were included in a
multiple logistic regression analysis together with those
significant predictors from the morphologic analysis (mitot-
ic count, lymphocytic infiltration, and continuous pushing
margins) (Table 5). ER status was the most significant risk
factor in the regression analysis. No other factor was
individually significant once ER status was taken into
account. The odds ratio associated with HER-2 positivity
(0.16) was identical to that in the single-factor analysis, but
this was not quite statistically significant in the multiple
regression (P  .067).
Table 2. Kappa Coefficients for Interobserver Variation
Positivity Intensity Percentage of Cells Stained
Kappa 95% CI Kappa 95% CI Kappa 95% CI
ER 0.95 0.92-0.98 0.87 0.83-0.89 0.87 0.84-0.89
PR 0.70 0.63-0.76 0.67 0.62-0.72 0.70 0.65-0.75
HER-2 0.83 0.72-0.92
p53 0.63 0.59-0.72 0.75 0.71-0.78 0.76 0.72-0.81
Abbreviation: CI, confidence interval.
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We also conducted an analysis including grade and ER
status, because grade is more likely to be routinely available
than the more detailed morphologic characteristics. There
was some suggestion of higher grade in BRCA1 tumors after
adjusting for ER status. This was apparent in both the
ER-negative and ER-positive groups, but again the effect
was not statistically significant (Table 6).
DISCUSSION
To date, most if not all studies investigating the molecular
profile of BRCA-associated tumors have been performed on
relatively small numbers of cases, making statistical analy-
sis of individual studies difficult. However, the combined
data in the literature is beginning to provide a glimpse of the
unique immunohistochemical and molecular profile of
BRCA1- and BRCA2-associated tumors.6,17,18
In previous reports,1,2 we have demonstrated that the
pathology of breast cancers arising in BRCA1 mutation
carriers differs from that observed in cancers from BRCA2
mutation carriers and that both differ from age-matched
breast cancers unselected for family history. We have now
compared the immunophenotype of tumors from patients
Table 3. Distribution of Immunohistochemical Features in Familial and Unselected Breast Cancers
Controls BRCA1 BRCA2
No. % No. % No. %
ER
Intensity
Negative 72 35 293 90 35 34
Low 66 32 16 5 20 19
Medium 40 20 7 2 28 27
High 26 13 9 3 21 20
Percentage of cells stained
 1% 74 36 293 90 35 34
1-10% 3 1 2 1 4 4
11-25% 7 3 5 2 4 4
26-50% 14 7 6 2 5 5
51-75% 30 15 9 3 21 20
76% 76 37 9 3 35 34
PR
Intensity
Negative 75 41 255 79 48 45
Low 39 21 42 13 20 19
Medium 33 18 14 4 26 25
High 58 31 10 4 12 11
Percentage of cells stained
 1% 79 39 264 82 49 46
1-10% 34 17 19 6 13 12
11-25% 14 7 14 4 6 6
26-50% 12 6 11 3 11 10
51-75% 20 10 7 3 13 12
76% 45 22 6 2 14 13
HER-2
Negative 175 85 317 97 107 97
Positive 31 15 9 3 3 3
p53
Intensity
Negative 80 39 137 42 48 45
Low 53 26 25 8 22 21
Medium 39 19 52 16 22 21
High 34 17 111 34 15 14
Percentage of cells stained
 1% 106 51 148 45 59 55
1-10% 34 17 13 4 7 7
11-25% 11 5 13 4 4 4
26-50% 10 5 9 3 6 6
51-75% 17 8 33 10 12 11
76% 28 14 110 34 19 18
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with BRCA1 or BRCA2 mutations with breast cancers
unselected for family history.
ER has become one of the most important prognostic and
predictive markers for breast cancer.19 The expression of
ER is inversely correlated with tumor grade.20 Because
BRCA1- and BRCA2-associated tumors are overall higher
grade than sporadic cancers, they would be predicted to be
more often ER-negative. Indeed, a number of studies have
shown a low level of ER expression in familial breast
cancers,6,11,21-23 particularly those associated with BRCA1.
Our study has confirmed that the large majority of tumors in
BRCA1 carriers are ER-negative, but that, in contrast, the
expression of ER in BRCA2 tumors appears to be similar to
that in sporadic breast cancers.21,22 (Although the BRCA2
series was smaller than the BRCA1 series, the study still had
adequate power to detect an effect of ER status—a differ-
Table 4. Odds Ratios for Individual Factors, Adjusting for Age and Pathologist
Factor/Level
BRCA1 BRCA2
Odds Ratio 95% CI Odds Ratio 95% CI
ER intensity
Negative 1.0 1.0
Low 0.062 0.017-0.23 0.56 0.26-1.21
Medium 0.037 0.008-0.17 1.29 0.54-3.05
High 0.13 0.024-0.65 1.70 0.64-4.53
X23  27.81 (P  .0001) X23  6.00 (P  .11)
X21  18.72 (P  .0001) X21  0.48
ER percentage of cells stained
 1% 1.0 1.0
1-10% 0.14 0.023-0.91 1.35 0.12-15.42
11-25% 0.15 0.040-0.58 0.88 0.27-2.88
26-50% 0.12 0.031-0.49 0.76 0.25-2.29
51-75% 0.082 0.020-0.34 1.49 0.64-3.49
76% 0.028 0.003-0.27 0.88 0.42-1.85
X25  20.11 (P  .001) X25  2.43
X21  18.42 (P  .0001) X21  0.00
PR intensity
Negative 1.0 1.0
Low 0.26 0.11-0.62 0.65 0.31-1.38
Medium 0.11 0.029-0.39 1.11 0.47-2.64
High 0.083 0.019-0.37 0.43 0.16-1.14
X23  16.61 (P  .0008) X23  4.71
X21  16.05 (P  .0001) X23  1.58
HER-2
Negative 1.0 1.0
Positive 0.16 0.029-0.72 0.13 0.008-2.0
X21  5.55 (P  .018) X21  2.15
p53 intensity
Negative 1.0 1.0
Low 0.32 0.14-0.72 0.69 0.32-1.52
Med 0.93 0.39-2.21 1.15 0.51-2.61
High 2.28 0.81-6.42 0.84 0.33-2.13
X23  12.89 (P  .005) X23  1.56
X21  0.28 X21  0.08
p53 percentage of cells stained
 1% 1.0 1.0
1-10% 0.31 0.13-0.71 0.36 0.12-1.06
11-25% 1.79 0.31-10.26 1.25 0.30-5.21
26-50% 1.43 0.28-7.20 2.05 0.42-9.90
51-75% 2.29 0.47-11.16 2.12 0.61-7.32
76-100% 3.19 1.09-9.30 1.34 0.54-3.34
X25  16.36 (P  .006) X25  6.36
X21  2.37 (P  .12) X21  1.03
51% 3.25 1.30-8.13 1.66 0.77-3.55
X21  6.36 (P  .01) X21  1.69
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ence comparable to that seen in BRCA1 would have been
highly significant.) This difference in behavior is mirrored
by the different age distribution of tumors in BRCA1 and
BRCA2 carriers: tumors in BRCA1 carriers occur at a
younger age, with the incidence rate relative to population
rates decreasing rapidly with increasing age, whereas
BRCA2 tumors have an age distribution much closer to that
in the general population.16
The multiple regression analysis indicated that ER status
was the strongest predictor of BRCA1 status. The effect of
factors including grade and lymphocytic infiltration were
much weaker after ER status had been accounted for. The
effect of ER status was seen clearly even in low-grade
tumors, suggesting that the tumors arose in receptor-nega-
tive cells. This is consistent with the previous observations
that both the invasive and in situ component in BRCA
tumors has a similar status with respect to steroid hormone
receptor expression. Taken together, these observations
suggest a model in which BRCA1 tumors are arising as a
result of a quite distinct, hormone-independent mechanism
than BRCA2 tumors and tumors in noncarriers, possibly in
a different subpopulation of cells. However, the alternative
hypothesis that BRCA1 tumors develop aggressively and
lose hormone dependence in progression cannot be ruled
out definitively. Whatever the mechanism, these data pre-
dict that cancers arising in BRCA1 carriers will be relatively
resistant to hormonal therapy. They also cast doubt (partic-
ularly if the BRCA1 tumors are receptor-negative ab initio)
on the likely efficacy of hormonal chemoprevention, such as
tamoxifen, in BRCA1 carriers, although this clearly requires
empiric evaluation. Because most of the ER-positive cells in
the normal breast are not the same as the proliferative
compartment, this argument may not be entirely valid.24
The detection of ER immunohistochemically does not
necessarily reflect functional competence, and a proportion
of breast cancers expressing ER are known to be resistant to
antiestrogen therapy. The function of ER is dependent on
the ability to transactivate so-called ER-dependent genes.
Expression of PR and PS2 protein is indirect evidence of
retained transcriptional activation activity of ER, and it has
been shown that PR and PS2 expression have stronger
correlation with prognosis in breast cancer than ER expres-
sion alone.25 Osin et al21 have shown that although nine of
40 familial breast cancer cases were ER-positive, only two
of these were also PR-positive. This suggests that even in
cases where ER receptors could be identified immunohisto-
chemically, their functional ability may be compromised.
A large number of studies have been performed on the
functional role of HER-2 oncogene in breast cancer. HER-2
product is a tyrosine kinase receptor belonging to the same
family as epidermal growth factor receptor. It is overex-
pressed in approximately 20% to 30% of high-grade inva-
sive breast cancers and has been shown to be a valuable
prognostic indicator. HER-2 status also predicts response to
antiestrogen and cytotoxic chemotherapy. Antibodies di-
rected against the HER-2 protein have attracted a lot of
attention recently because of the availability of the mono-
clonal antibody Herceptin for treatment of breast cancer.12
Clearly, the role of HER-2 in familial breast cancer would
therefore be of interest.
Data on HER-2 in familial breast cancer are limited and
conflicting. Robson et al11 and Armes et al23 have not
Table 5. Multiple Regression Analysis of Factors Related to BRCA1
Factor Odds Ratio 95% CI
ER
Positive 0.082 0.022-0.30
X21  13.87 (P  .0002)
HER-2
Positive 0.12 0.006-2.16
X21  2.08 (P  .15)
Mitotic count
0-4 1.0
5-9 0.56 0.16-2.01
10-19 0.84 0.22-3.30
20-39 1.77 0.37-8.39
40 1.27 0.15-10.88
X24  2.47
X21  0.06
Pushing margins
None 1.0
 25% 0.92 0.092-9.14
25-50% 1.33 0.069-25.75
 50% 1.20 0.10-14.33
X23  0.06
X21  0.04
Lymphocytic infiltration
None 1.0
Mild 1.68 0.51-5.57
Severe 2.36 0.15-37.67
X22  1.02
X21  0.58
Table 6. Odds Ratios for BRCA1 Positivity Related to ER and Grade, by
Multiple Regression Analysis
Factor Odds Ratio 95% CI
ER
Positive 0.076 0.026-0.22
X21  23.09 (P  .0001)
Grade
1 1.0
2 1.46 0.29-7.28
3 2.24 0.43-11.68
X22  1.20
X21  0.68
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shown a difference in HER-2 expression between sporadic
and familial cancers. However, the study by Johannsson et
al6 demonstrated that HER-2 expression in BRCA1-associ-
ated cancers is lower than would be predicted on the basis
of their histologic grade. This is indeed the conclusion of
this study. Only 3% of BRCA1 and 3% of BRCA2 cases
were positive for HER-2, compared with 15% of sporadic
cases. The proportion of sporadic cancers positive for
HER-2 is on the lower side of data within the literature. This
may be a reflection of the choice of antibody, the stringent
criteria used to score positive results, or a real population
difference. In any event, the difference to familial breast
cancer is striking, especially in view of the overall higher
grade of BRCA1 and BRCA2 tumors. Taken at face value,
Herceptin is unlikely to play a large role in the management
of breast cancer in patients harboring mutations in BRCA1
and BRCA2.
p53 protein is an important guardian of stability and
integrity of the genome, acting to prevent cell proliferation
after DNA damage and activating apoptosis in case of
unrepairable damage.26 Mutations in the TP53 gene are the
most common genetic alterations in human cancers and are
encountered in 20% to 40% of sporadic breast cancers. The
frequency of these mutations correlates with tumor grade. It
has been demonstrated that p53 missense mutations results
in p53 protein with an increased half-life. It is also clear,
however, that not all truncating mutations lead to protein
changes that can be detected using immunohistochemistry.
Despite this, detection of p53 protein by immunohistochem-
istry has become a routine method in pathology practice,
and the presence of detectable p53 protein is an important
prognostic marker that correlates with higher histopatho-
logic grade, increased mitotic activity, aggressive behavior,
and therefore a worse prognosis.27-30
We did not see a clear relationship between p53 staining
and BRCA1 status. The proportion of tumors showing
strong p53 staining was higher than in controls, as was the
proportion with staining in more than 50% of cells (44% v
22%). However, the proportion with weak staining was
actually lower in BRCA1 carriers. These differences are less
marked than those reported by Crook et al,31,32 who
reported that BRCA-associated tumors were more often
p53-positive compared with grade-matched sporadic breast
cancers (77% BRCA1, 45% BRCA2, and 35% sporadic).
Sobol et al33 reported 41% positivity in BRCA1 cases
compared with 17.5% in sporadic cancers using the DO1
antibody. Further evidence for an important role for p53 in
familial breast cancer comes from the detection of muta-
tions at a higher frequency compared with sporadic cancers.
The mutations in BRCA-associated cancers were often
multiple and their locations unusual, which is in marked
contrast to sporadic cancer.34 Studies of p53 gene function
in BRCA tumors have been performed using in vitro
models. These show that the identified mutants are unique
not only in their number and location but also in their
function. The mutants retain some of their wild p53-
dependent activities, such as transactivation, suppression of
proliferation, and apoptosis induction (in particular, through
PIG3 transactivation). At the same time, these mutants fail
to suppress transformation and exhibit gain of function.35
The retained ability of some of these novel mutants to
transactivate MDM2 may explain the absence of immuno-
detectable p53 in some BRCA tumors with p53 mutations.
This can occur because of the degradation of the p53 protein
by the MDM2-regulated ubiquitin-dependent pathway.
BRCA1 and BRCA2 proteins are thought to have a role
in DNA repair.36 Inactivation of the gene(s) will lead to cell
cycle arrest because of activation of p53. This may explain
why breast cancers in patients with inactivation of BRCA1
and BRCA2 show mutations in p53. This view is consistent
with data from BRCA1 knockout mice where the embryonic
lethality can be partially rescued by knocking out p53.37,38
The immunohistochemical analysis provides a new and
powerful predictor of BRCA1 mutation status that could
augment risk assessment on the basis of family history of
breast/ovarian cancer, particularly because ER status is
routinely available in many centers. The estimated carrier
probabilities in women with breast cancer, on the basis of
age at diagnosis, ER status, grade, and age, are listed in
Table 7. The observation that a tumor is ER-negative will
roughly double the probability that the individual is a
BRCA1 carrier, whereas finding that the tumor is ER-
positive will reduce the probability by approximately five-
fold. Thus, for example, the probability that women diag-
nosed with breast cancer at age 30 to 34 harbor a BRCA1
mutation is approximately 5%. On the basis of our results,
this would rise to approximately 27% for ER-negative grade
3 tumors, and would be at least 10% for ER-negative tumors
regardless of grade. At this level of risk, predictive testing
might well be considered justified, even in the absence of
information on family history, particularly in view of the
high risk of a subsequent breast cancer or ovarian cancer.39
Thus, inclusion of pathologic features into risk assessment
would help identify patients most likely to harbor muta-
tions, hence reducing the costs and psychological morbidity
associated with genetic testing. There is emerging data from
smaller studies that the use of morphology and immunohis-
tochemical profile is likely to be useful in clinical prac-
tice.40-42 Hence, although this is not the first report to
consider this element, it is the largest series of cases
analyzed to date that provided risk estimates that can be
used in clinical practice. Further prospective studies will be
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needed to evaluate its utility in the clinic. The inclusion of
HER-2 positivity would further add to the predictive value.
Unfortunately, prediction of BRCA2 status remains
problematic.
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APPENDIX
The following institutions and members of the Breast Cancer Linkage Consortium also participated in the study: Sections of Cancer Genetics and
Epidemiology, Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey (Michael R. Stratton, MD, and Julian Peto, PhD) and London
School of Hygiene and Tropical Medicine, London (Julian Peto, PhD); Department of Pathology, Western Infirmary, University of Glasgow,
Scotland (Barry A. Gusterson, MD); Department of Pathology, University of Liverpool, Liverpool (John P. Sloane, MD, deceased); CRC Cancer
Genetics Group, Paterson Institute for Cancer Research (Jenny Varley, PhD) and Department of Medical Genetics, St Mary’s Hospital, Manchester
(Fiona Lalloo, MD); and Medical Genetics, Department of Medicine and Therapeutics, University of Aberdeen, Foresterhill, Aberdeen (Neva
Haites, MD), United Kingdom; Centre Jean-Perrin, Clermont-Ferrand (Frederique Penault-Llorca, MD, and Yves-Jean Bignon, PhD); University
Hospital, Nantes (Christine Maugard, PhD, and Maryse Fiche, MD); and Department of Genetic Oncology and Cancer Control, INSERM EPI 9939,
Paoli Calmettes Institute, Marseille, France (Hagay Sobol); Departments of Genetics (Javier Benitez, MD) and Pathology (Carmen Rivas, MD),
Fundacio´n Jime´nez Dı´az, Autonomous University of Madrid, Madrid, Spain; Departments of Experimental Oncology (Paolo Radice, PhD) and
Pathology (Silvana Pilotti, MD), Istituto Nazionale Tumori, Milan, Italy; Department of Obstetrics and Gynaecology, General Hospital, University
of Vienna, Vienna, Austria (Teresa Wagner, MD); National Institute of Oncology, Department of Molecular Biology, Budapest, Hungary (Edith
Olah, PhD); Department of Medicine, Trinity College Medical School, St James Hospital, Dublin, Ireland (Peter A. Daly, MD); Max-Delbruck-
Centrum fur Moleculare Medizin, Tumorgenetik, Berlin (Siegfried Scherneck, PhD); Department of Obstetrics and Gynecology, Friedrich
Alexander University, Erlangen (Matthias W. Beckmann, MD, and Carolin Nestle-Kra¨mling, MD); and Deutsches Krebsforschungszentrum,
Divisions of Epidemiology and Molecular Genome Analysis, Heidelberg, Germany (Ute Hamann, PhD, and Jenny Chang-Claude, PhD); and
Department of Genetics and Pathology, Leiden University, Leiden (Peter Devilee, PhD, and Cees J. Cornelisse, PhD); and Department of Clinical
Genetics and Medical Oncology, Daniel den Hoed Cancer Centre, Erasmus University Medical Centre Rotterdam, Rotterdam, the Netherlands (Jan
G.M. Klijn, PhD, and Hanne Meijers-Heijboer, MD).
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